BioSpace News Archive

Universal Health Services, Inc. (NYSE: UHS) announced today that it will report results for its second quarter ended June 30, 2022, after the market closes on Monday, July 25, 2022.

CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release second quarter 2022 financial and operating results after market close on Thursday, July 28th, 2022.

ENB Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics targeting the endothelin B receptor inhibitor, announced that Sumayah Jamal, MD-PhD, President, Co-Founder, and CSO of ENB Therapeutics, will be participating in the SVB Securities Biopharma Private Company Connect to be held virtually on July 20th and 21st.

Voltron Therapeutics, Inc., a Lucius Partners portfolio company, today announced that data from the previously announce Study ‘098 demonstrated clear Proof-of Concept for VTX-067 in the treatment of HPV related cancers.

Cordis, a global leader in cardiovascular technologies, today announced the start of the RADIANCY pre-market clinical study in Europe.

Kubota Vision Inc. (“Kubota Vision” or the “Company”), a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced the publication of a new paper in the journal Scientific Reports, entitled “Biometric and refractive changes following the monocular application of peripheral myopic defocus using a novel augmented-reality optical system in adults.”